Junshi Biosciences and Rxilient Biotech Form JV to Commercialize Tuoyi in Southeast Asia
China-based biopharmaceutical company Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a joint venture (JV)...
PD-1/L1
BJ Bioscience Partners with MSD for Phase I Clinical Trial of BJ-001 and Keytruda
Shanghai-based biotech BJ Bioscience Inc. has announced a clinical trial collaboration and supply agreement with...
RemeGen’s RC48 Receives Two Clinical Trial Approvals for Breast Cancer Treatments
RemeGen Ltd (HKG: 9995) has announced the receipt of two clinical trial approvals for its...
Henlius Biotech’s Serplulimab Accepted for EMA Review for ES-SCLC Treatment
Shanghai Henlius Biotech (HKG: 2696) has announced that the European Medicines Agency (EMA) has accepted...
Biokin’s BL-B01D1 Receives NMPA Approval for Phase II Solid Tumor Study
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has received approval...
3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials
China-based 3SBio Inc. (HKG: 1530) released its 2022 financial report, recording revenues of RMB 6.859...
Jacobio Pharma Partners with Merck to Evaluate CD73 mAb and Keytruda Combination
China-based Jacobio Pharma (HKG: 1167) has announced a clinical partnership with Merck, Sharp & Dohme...
Akeso Biopharma Enrolls First Subject in Phase III Study of Cadonilimab for Gastric Cancer
China-based Akeso Biopharma (HKG: 9926) has announced the enrollment of the first subject in a...
CSPC Pharmaceutical’s PD-1 Monoclonal Antibody Enlangsubai Completes NMPA Market Approval Filing
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the completion of a market approval...
Akeso Biopharma and Shanghai Pharmaceuticals Collaborate on Liposarcoma Treatment
China-based Akeso Biopharma (HKG: 9926) has announced a strategic collaboration agreement with compatriot firm Shanghai...
Huahai Pharma’s HB0025 Receives NMPA Approval for Clinical Trials
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clinical...
Hengrui’s Adebrelimab Receives NMPA Approval for Lung Cancer Treatment
Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that it has received marketing approval from the...
Merck Reports 12.9% Sales Growth in 2022 Annual Report
German major Merck (NYSE: MRK) released its 2022 annual report this week, showing a robust...
Oricell Therapeutics Closes $45M Series B1 Round for Cellular Immunotherapy
China-based tumor cellular immunotherapeutics developer Oricell Therapeutics Co., Ltd has announced the closing of a...
CStone’s PD-L1 Inhibitor Sugemalimab Accepted for Review in Gastric Cancer
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the National Medical Products Administration (NMPA) has...
BeiGene’s Tislelizumab Approved for Gastric Tumors in China
BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has revealed that its programmed death-1 (PD-1) inhibitor...
CStone’s Sugemalimab Accepted for EU Marketing Authorization by EMA
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the European Medicine Agency (EMA) has accepted...
Junshi Biosciences’ PD-1 Inhibitor Tuoyi Shows Promise in Phase III TNBC Study
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced significant progress in the Phase...
Junshi Biosciences Seeks UK MHRA Approval for PD-1 Inhibitor Tuoyi
Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biotech firm, has announced the submission...
Hengrui Pharmaceuticals Gains NMPA Approval for SHR-A1921 Clinical Study
Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving the go-ahead from the National Medical Products...